Shanghai Pharmaceuticals Holding Co., Ltd
SHPMYOTCHealthcare● Active
$7.60
+$0.00(+0.00%)
Market Cap$5.6B
P/E Ratio—
52W High$8.32
52W Low$6.83
Shanghai Pharmaceuticals Holding Co., Ltd（SHPMY）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · SHPMY · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $283.58B | $275.25B | $260.30B | $231.98B | $215.82B |
| Cost of Revenue | $253.16B | $244.62B | $228.97B | $201.49B | $187.28B |
| Gross Profit | $30.42B | $30.63B | $31.33B | $30.49B | $28.54B |
| Gross Margin %(computed) | 10.73% | 11.13% | 12.04% | 13.14% | 13.23% |
| Operating Expenses | |||||
| R&D Expenses | $2.34B | $2.39B | $2.20B | $2.11B | $1.99B |
| G&A Expenses | $5.31B | $1.77B | $1.71B | $1.20B | $1.41B |
| Total Operating Expenses | $20.47B | $22.49B | $23.66B | $21.71B | $20.62B |
| Operating Income | $9.94B | $8.14B | $7.67B | $9.01B | $8.21B |
| Operating Margin %(computed) | 3.51% | 2.96% | 2.95% | 3.89% | 3.80% |
| Interest Income | $0.40B | $0.52B | $0.39B | $0.44B | $0.34B |
| Interest Expense | $1.69B | $1.63B | $1.66B | $1.69B | $1.52B |
| Income Before Tax | $9.82B | $8.02B | $7.05B | $8.81B | $8.14B |
| Income Tax Expense | $2.85B | $2.15B | $1.89B | $1.82B | $1.87B |
| Net Income | $5.72B | $4.55B | $3.77B | $5.62B | $5.09B |
| Net Margin %(computed) | 2.02% | 1.65% | 1.45% | 2.42% | 2.36% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $7.70 | $6.15 | $5.10 | $8.05 | $8.95 |
| Wtd Avg Shares | 0.74B | 0.74B | 0.74B | 0.70B | 0.57B |
| EBITDA | $14.37B | $12.06B | $10.90B | $12.42B | $11.27B |
| EBITDA Margin %(computed) | 5.07% | 4.38% | 4.19% | 5.35% | 5.22% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · CNY · B
深入了解Shanghai Pharmaceuticals Holding Co., Ltd
关于Shanghai Pharmaceuticals Holding Co., Ltd（SHPMY）损益表
Shanghai Pharmaceuticals Holding Co., Ltd（SHPMY）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，SHPMY实现营收$283.58B，毛利润$30.42B（毛利率10.73%），净利润$5.72B（净利率2.02%）。
常见问题
SHPMY · 4 问Shanghai Pharmaceuticals Holding Co., Ltd（SHPMY）2025财年营收为$283.58B，同比up3.0%。
SHPMY revenueSHPMY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09